Survey:12% Of Adults Take A GLP-1 Medication For Diabetes, Obesity, Other Condition

Twelve percent of 1,350 U.S. adults who responded to the 2025 KFF Health Tracker Poll said they were currently taking a GLP-1 medication as treatment for diabetes, obesity, or for other approved uses, such as cardiovascular disease and sleep apnea.

Brand names for this class of medications with indications for diabetes include Ozempic, Mounjaro, Rybelsus, and Trulicity. Brand names for GLP-1 medications to treat obesity include Wegovy and Zepbound. Among those taking a GLP-1 medication, use was highest among adults who reported being diagnosed with conditions the medications are approved to treat.

Diabetes: reported by . . .